Abstract 129: Older Age and Shorter Time from Symptom Onset Positively Impacts Outcomes in Moderate Severity Stroke Patients in SENTIS Trial
Background: A number of recent acute ischemic stroke trials have shown that patients with moderate severity strokes respond most positively to interventional treatments. Similarly, the SENTIS Trial showed that patients with moderate severity stroke had significantly better outcome when treated with NeuroFlo. The current report is a post hoc analysis of patients with moderate stroke in the SENTIS Trial.
Methods: SENTIS was a prospective randomized trial of the safety and efficacy of NeuroFlo treatment. A total of 515 patients were enrolled at 68 centers in 9 countries. Modified Rankin Scale (mRS) scores at 90 days were dichotomized into 0-2 versus 3-6 for patients with baseline National Institute of Health Stroke Scale (NIHSS) scores of 8 to 14, and compared between the treated and non-treated groups. Additionally, we evaluated the impact of age, time from symptom onset (TFSO) to randomization, and occlusion location on outcomes in this patient cohort.
Results: Of the 515 patients enrolled in SENTIS, 219 patients (42%) with NIHSS 8 to 14 were available for analysis. The table below lists the odds ratio (OR) with 95% confidence intervals (CI) and p-values for the cohorts evaluated.
Conclusion: Patients with moderate stroke severity had significantly better outcomes in the treated group compared to the non-treated group in this post hoc analysis of over 40% of patients enrolled in the SENTIS Trial. Additionally, patients 70 years and older and those with TFSO ≤5 hours had significantly better outcomes. To ensure the best efficacy analysis of new ischemic stroke treatments, future studies may focus on patients with moderate severity strokes.
- © 2012 by American Heart Association, Inc.